

Effectiveness of mRNA-1273 against Delta, Mu, and other emerging variants

SUPPLEMENTARY APPENDIX

Authors: Katia J. Bruxvoort, PhD,^{1,2} Lina S. Sy, MPH,¹ Lei Qian, PhD,¹ Bradley K. Ackerson, MD,¹ Yi Luo, PhD,¹ Gina S. Lee, MPH,¹ Yun Tian, MS,¹ Ana Florea, PhD,¹ Michael Aragones, MD,¹ Julia E. Tubert, MPH,¹ Harpreet S. Takhar, MPH,¹ Jennifer Ku, PhD,¹ Yamuna D. Paila, PhD,³ Carla A. Talarico, PhD,³ Hung Fu Tseng, PhD^{1,4}

Affiliations: ¹Kaiser Permanente Southern California, 100 S. Los Robles Ave., Pasadena, CA 91101, USA;
²University of Alabama at Birmingham, 1665 University Blvd, Birmingham, AL 35233, USA; ³Moderna Inc., 200 Technology Square, Cambridge, MA 02139, USA; ⁴Kaiser Permanente Bernard J. Tyson School of Medicine, 98 S. Los Robles Ave., Pasadena, CA 91101, USA

Contents

Supplementary Methods	3
Table S1. ICD-10 diagnosis codes for subgroup conditions and for covariates to be considered as potential confounders	4
Table S2. Characteristics of SARS-CoV-2 test-positive Alpha ^a cases and test-negative controls (2-dose analysis).....	5
Table S3. Characteristics of SARS-CoV-2 test-positive Epsilon ^a cases and test-negative controls (2-dose analysis).....	7
Table S4. Characteristics of SARS-CoV-2 test-positive Gamma ^a cases and test-negative controls (2-dose analysis)	9
Table S5. Characteristics of SARS-CoV-2 test-positive Iota ^a cases and test-negative controls (2-dose analysis).....	11
Table S6. Characteristics of SARS-CoV-2 test-positive Mu ^a cases and test-negative controls (2-dose analysis).....	13
Table S7. Characteristics of SARS-CoV-2 test-positive other ^a variant cases and test-negative controls (2-dose analysis)	15
Table S8. Characteristics of SARS-CoV-2 test-positive unidentified variants cases and test-negative controls (2-dose analysis).....	17
Table S9. Vaccine effectiveness of 2 doses of mRNA-1273 against infection with SARS-CoV-2 variants.....	19
Table S10. Vaccine effectiveness of 1 dose of mRNA-1273 against infection with SARS-CoV-2 variants	20
Table S11. Vaccine effectiveness of 2 doses of mRNA-1273 against infection with SARS-CoV-2 variants by time since vaccination	21
Figure S1. Distribution of SARS-CoV-2 variants by mRNA-1273 vaccination status	22
Figure S2. Distribution of SARS-CoV-2 variants by month of specimen collection.....	23
Figure S3. Vaccine effectiveness of 2 doses of mRNA-1273 against Delta infection by time since vaccination and age group	24

Supplementary Methods

Whole genome sequencing approach

KPSC began sending all positive SARS-CoV-2 specimens to a commercial laboratory (Helix, California, USA) for whole genome sequencing (WGS) beginning March 2021. In Helix workflow, SARS-CoV-2 genome capture was accomplished using hybridization capture with the xGen COVID-19 Capture Panel (Integrated DNA Technologies, Iowa, USA). Specimens were sequenced using the NovaSeq 6000 Sequencing System S1 Reagent Kit v1.5 (300 cycles) (Illumina, California, USA). Sequence reads were aligned to the SARS-CoV-2 reference genome (NCBI accession NC_045512.2) and the human transcriptome (GENCODE v37) using BWA-MEM, and variants were called using the Haplotyper algorithm (Sentieon Inc, California, USA). Consensus sequences (FASTA) required each allele to have at least 5 unique reads with at least 80% of the reads supporting the allele.

Power calculations

Analyses were conducted for variants with at least 20 cases, based on the following power calculations. For a 1:5 matched test-negative design, assuming a 60% vaccination rate (2 doses of mRNA-1273) in test-negative controls, 20 cases were needed to detect a vaccine effectiveness of 0.8 with 80% statistical power.

Table S1. ICD-10 diagnosis codes for subgroup conditions and for covariates to be considered as potential confounders

Covariate	ICD-10 codes
Immunosuppressant conditions	
Lymphoma/leukemia	C81.*-C86.*, C88.*, C90.*-C96.*, D45, D46.*
Congenital and other immunodeficiencies	D61.09, D61.3, D61.82, D61.9, D70.0, D71, D80.0, D80.1, D80.5, D80.8, D81.*, D82.*, D83.*, D84.0, D84.1, D84.89, D84.9, D89.81*, D89.82, D89.9, E31.0, E70.330, G11.3, Q82.4, Q89.0*
Asplenia/hyposplenia	D57.00, D57.01, D57.02, D57.1, D57.2, D57.20, D57.21, D57.211, D57.212, D57.219, D57.4, D57.40, D57.41, D57.411, D57.412, D57.419, D57.8, D57.80, D57.81, D57.811, D57.812, D57.819, D73.0, Q89.01, Q89.09, Z90.81
Autoimmune conditions	
Rheumatic disease	M05.*, M06.*, M31.5, M32.*-M34.*, M35.1, M35.3, M36.0
Inflammatory bowel disease	K50.*, K51.*
Psoriasis	L40.*
Psoriatic arthritis	L40.5*
Multiple sclerosis	G35
Systemic lupus erythematosus	M32.1, M32.8, M32.9
Charlson comorbidity	
Myocardial Infarction	I21.*, I22.*, I25.2
Congestive Heart Failure	I09.9, I11.0, I13.0, I13.2, I25.5, I42.0, I42.5-I42.9, I43.*, I50.*, P29.0
Peripheral Vascular Disease	I70.*, I71.*, I73.1, I73.8*, I73.9, I77.1, I79.0, I79.2, K55.1, K55.8, K55.9, Z95.8*, Z95.9
Cerebrovascular Disease	G45.*, G46.*, H34.0*, I60.*-I69.*
Connective tissue disease	M05.*, M06.*, M31.5, M32.*-M34.*, M35.1, M35.3, M36.0
Dementia	F00.*-F03.*, F05.1, G30.*, G31.1
Chronic pulmonary disease	I27.8*, I27.9, J40.*-J47.*, J60.*-J67.*, J68.4, J70.1, J70.3
Peptic ulcer disease	K25.*-K28.*
Diabetes mellitus	E10.*-E14.*
Paraplegia and hemiplegia	G04.1, G11.4, G80.1, G80.2, G81.*, G82.*, G83.0, G83.1*-G83.3*, G83.4, G83.9
Renal disease	I12.0, I12.9, I13.1*, N03.2-N03.7, N05.2-N05.7, N18.*, N19.*, N25.0, Z49.0*-Z49.2*, Z94.0, Z99.2
Liver disease	B18.*, I85.0*, I86.4, I98.2, K70.0, K70.1*-K70.4*, K70.9, K71.1*, K71.3, K71.4, K71.5*, K71.7, K72.1*, K72.9*, K73.*, K74.*, K76.0, K76.2-K76.7, K76.8*, K76.9, Z94.4
Cancer: any malignancy, including lymphoma and leukemia, except malignant neoplasm of skin	C00.*-C26.*, C30.*-C34.*, C37.*-C41.*, C43.*, C45.*-C58.*, C60.*-C76.*, C81.*- C85.*, C88.*, C90.*-C97.*
Metastatic Solid Tumor	C77.*-C80.*
Chronic diseases	
Kidney disease	I12.0, I12.9, I13.1*, N03.2-N03.7, N05.2-N05.7, N18.*, N19.*, N25.0, Z49.0*-Z49.2*, Z94.0, Z99.2
Heart disease	I21.*, I22.*, I25.2, I09.9, I11.0, I13.0, I13.2, I25.5, I42.0, I42.5-I42.9, I43.*, I50.*, P29.0
Lung disease	I27.8*, I27.9, J40.*-J47.*, J60.*-J67.*, J68.4, J70.1, J70.3
Liver disease	B18.*, I85.0*, I86.4, I98.2, K70.0, K70.1*-K70.4*, K70.9, K71.1*, K71.3, K71.4, K71.5*, K71.7, K72.1*, K72.9*, K73.*, K74.*, K76.0, K76.2-K76.7, K76.8*, K76.9, Z94.4
Diabetes mellitus	E10.*-E14.*

Table S2. Characteristics of SARS-CoV-2 test-positive Alpha^a cases and test-negative controls (2-dose analysis)

	Test Positive (Alpha) N=1422 n (%)	Test Negative N=7110 n (%)	p value	ASD
Age at specimen collection date, years			N/A	N/A
18-44	839 (59.0)	4195 (59.0)		
45-64	498 (35.0)	2490 (35.0)		
65-74	64 (4.5)	320 (4.5)		
≥75	21 (1.5)	105 (1.5)		
Sex			N/A	N/A
Female	780 (54.9)	3900 (54.9)		
Male	642 (45.1)	3210 (45.1)		
Race/ethnicity			N/A	N/A
Non-Hispanic White	479 (33.7)	2395 (33.7)		
Non-Hispanic Black	189 (13.3)	945 (13.3)		
Hispanic	588 (41.4)	2940 (41.4)		
Non-Hispanic Asian	56 (3.9)	280 (3.9)		
Other/Unknown	110 (7.7)	550 (7.7)		
BMI ^c			<0.0001	0.1651
<18.5	8 (0.6)	94 (1.3)		
18.5 - <25	269 (18.9)	1472 (20.7)		
25 - <30	361 (25.4)	2005 (28.2)		
30 - <35	300 (21.1)	1487 (20.9)		
35 - <40	165 (11.6)	792 (11.1)		
40 - <45	70 (4.9)	361 (5.1)		
≥45	61 (4.3)	242 (3.4)		
Unknown	188 (13.2)	657 (9.2)		
Smoking ^c			0.0003	0.1153
No	1040 (73.1)	5185 (72.9)		
Yes	232 (16.3)	1371 (19.3)		
Unknown	150 (10.5)	554 (7.8)		
Charlson comorbidity score ^b			<0.0001	0.1612
0	1152 (81.0)	5355 (75.3)		
1	165 (11.6)	916 (12.9)		
≥2	105 (7.4)	839 (11.8)		
Frailty index ^b			<0.0001	0.1923
Quartile 1	306 (21.5)	1693 (23.8)		
Quartile 2	465 (32.7)	1802 (25.3)		
Quartile 3	366 (25.7)	1767 (24.9)		
Quartile 4 (most frail)	285 (20.0)	1848 (26.0)		
Chronic diseases ^b				
Kidney disease	29 (2.0)	250 (3.5)	0.0043	0.0900
Heart disease	20 (1.4)	181 (2.5)	0.0097	0.0819
Lung disease	89 (6.3)	644 (9.1)	0.0006	0.1054
Liver disease	26 (1.8)	231 (3.2)	0.0042	0.0904
Diabetes	132 (9.3)	700 (9.8)	0.5139	0.0191
Immunocompromised ^e	28 (2.0)	305 (4.3)	<0.0001	0.1336
Autoimmune conditions ^{b,f}	29 (2.0)	191 (2.7)	0.1600	0.0426
Pregnant at specimen collection date	28 (2.0)	384 (5.4)	<0.0001	0.1829
History of COVID-19 diagnosis ^d	6 (0.4)	538 (7.6)	<0.0001	0.3711
History of SARS-CoV-2 molecular test ^d	727 (51.1)	3644 (51.3)	0.9305	0.0025
Number of outpatient and virtual visits ^b			<0.0001	0.3458
0	182 (12.8)	545 (7.7)		
1-4	511 (35.9)	1863 (26.2)		
5-10	358 (25.2)	1848 (26.0)		
≥11	371 (26.1)	2854 (40.1)		
Number of ED visits ^b			<0.0001	0.1851
0	1219 (85.7)	5620 (79.0)		
1	148 (10.4)	990 (13.9)		
≥2	55 (3.9)	500 (7.0)		
Number of hospitalizations ^b			0.0007	0.1233

0	1368 (96.2)	6670 (93.8)		
1	47 (3.3)	337 (4.7)		
≥2	7 (0.5)	103 (1.4)		
Preventive care ^b	686 (48.2)	4543 (63.9)	<0.0001	0.3194
Medicaid	164 (11.5)	764 (10.7)	0.3838	0.0250
Neighborhood median household income			0.1718	0.0729
< \$40,000	73 (5.1)	397 (5.6)		
\$40,000-\$59,999	278 (19.5)	1517 (21.3)		
\$60,000-\$79,999	399 (28.1)	1790 (25.2)		
\$80,000+	670 (47.1)	3399 (47.8)		
Unknown	2 (0.1)	7 (0.1)		
KPSC physician/employee	47 (3.3)	299 (4.2)	0.1162	0.0474
Month of specimen collection			<0.0001	0.1477
March 2021	345 (24.3)	1857 (26.1)		
April 2021	532 (37.4)	2269 (31.9)		
May 2021	345 (24.3)	1950 (27.4)		
June 2021	126 (8.9)	762 (10.7)		
July 2021	74 (5.2)	272 (3.8)		
Specimen type			<0.0001	0.4551
NP/OP swab	1376 (96.8)	5940 (83.5)		
Saliva (asymptomatic)	46 (3.2)	1170 (16.5)		

^a Alpha variant lineage: B.1.1.7

^b Defined in the one year prior to specimen collection date

^c Defined in the two years prior to specimen collection date

^d Defined based on all available medical records from March 1, 2020 to specimen collection date

^e Defined as HIV/AIDS; leukemia/lymphoma, congenital and other immunodeficiencies, asplenia/hyposplenia; organ transplant; immunosuppressant medications

^f Defined as rheumatoid arthritis, inflammatory bowel disease, psoriasis and psoriatic arthritis, multiple sclerosis, systemic lupus erythematosus
Medical center area not shown. There were differences in the distribution of cases and controls across the medical center areas.

Abbreviations: ASD, Absolute Standardized Difference; BMI, Body Mass Index; ED, Emergency Department; HIV/AIDS, Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome; NP/OP, nasopharyngeal/oropharyngeal

Table S3. Characteristics of SARS-CoV-2 test-positive Epsilon^a cases and test-negative controls (2-dose analysis)

	Test Positive (Epsilon) N=583 n (%)	Test Negative N=2915 n (%)	p value	ASD
Age at specimen collection date, years			N/A	N/A
18-44	346 (59.3)	1730 (59.3)		
45-64	216 (37.0)	1080 (37.0)		
65-74	16 (2.7)	80 (2.7)		
≥75	5 (0.9)	25 (0.9)		
Sex			N/A	N/A
Female	303 (52.0)	1515 (52.0)		
Male	280 (48.0)	1400 (48.0)		
Race/ethnicity			N/A	N/A
Non-Hispanic White	174 (29.8)	870 (29.8)		
Non-Hispanic Black	34 (5.8)	170 (5.8)		
Hispanic	307 (52.7)	1535 (52.7)		
Non-Hispanic Asian	35 (6.0)	175 (6.0)		
Other/Unknown	33 (5.7)	165 (5.7)		
BMI ^c			<0.0001	0.2537
<18.5	6 (1.0)	36 (1.2)		
18.5 - <25	105 (18.0)	616 (21.1)		
25 - <30	161 (27.6)	882 (30.3)		
30 - <35	117 (20.1)	625 (21.4)		
35 - <40	76 (13.0)	326 (11.2)		
40 - <45	21 (3.6)	129 (4.4)		
≥45	14 (2.4)	94 (3.2)		
Unknown	83 (14.2)	207 (7.1)		
Smoking ^c			<0.0001	0.2275
No	427 (73.2)	2151 (73.8)		
Yes	88 (15.1)	589 (20.2)		
Unknown	68 (11.7)	175 (6.0)		
Charlson comorbidity score ^b			<0.0001	0.2896
0	497 (85.2)	2152 (73.8)		
1	50 (8.6)	403 (13.8)		
≥2	36 (6.2)	360 (12.3)		
Frailty index ^b			<0.0001	0.3165
Quartile 1	149 (25.6)	726 (24.9)		
Quartile 2	204 (35.0)	666 (22.8)		
Quartile 3	131 (22.5)	748 (25.7)		
Quartile 4 (most frail)	99 (17.0)	775 (26.6)		
Chronic diseases ^b				
Kidney disease	8 (1.4)	96 (3.3)	0.0127	0.1275
Heart disease	3 (0.5)	75 (2.6)	0.0021	0.1675
Lung disease	27 (4.6)	268 (9.2)	0.0003	0.1806
Liver disease	13 (2.2)	111 (3.8)	0.0600	0.0923
Diabetes	40 (6.9)	307 (10.5)	0.0068	0.1305
Immunocompromised ^e	14 (2.4)	137 (4.7)	0.0127	0.1244
Autoimmune conditions ^{b,f}	20 (3.4)	86 (3.0)	0.5369	0.0273
Pregnant at specimen collection date	11 (1.9)	140 (4.8)	0.0016	0.1627
History of COVID-19 diagnosis ^d	2 (0.3)	220 (7.5)	<0.0001	0.3766
History of SARS-CoV-2 molecular test ^d	299 (51.3)	1678 (57.6)	0.0052	0.1263
Number of outpatient and virtual visits ^b			<0.0001	0.4151
0	65 (11.1)	164 (5.6)		
1-4	225 (38.6)	783 (26.9)		
5-10	152 (26.1)	773 (26.5)		
≥11	141 (24.2)	1195 (41.0)		
Number of ED visits ^b			<0.0001	0.3108
0	508 (87.1)	2243 (76.9)		

1	61 (10.5)	424 (14.5)		
≥2	14 (2.4)	248 (8.5)		
Number of hospitalizations ^b			0.0151	0.1496
0	556 (95.4)	2693 (92.4)		
1	24 (4.1)	166 (5.7)		
≥2	3 (0.5)	56 (1.9)		
Preventive care ^b , n()	314 (53.9)	1920 (65.9)	<0.0001	0.2468
Medicaid	59 (10.1)	284 (9.7)	0.7797	0.0126
Neighborhood median household income			0.8642	0.0572
< \$40,000	25 (4.3)	149 (5.1)		
\$40,000-\$59,999	122 (20.9)	611 (21.0)		
\$60,000-\$79,999	162 (27.8)	778 (26.7)		
\$80,000+	274 (47.0)	1375 (47.2)		
Unknown	0 (0.0)	2 (0.1)		
KPSC physician/employee	16 (2.7)	129 (4.4)	0.0631	0.0905
Month of specimen collection			0.2761	0.0977
March 2021	463 (79.4)	2310 (79.2)		
April 2021	110 (18.9)	516 (17.7)		
May 2021	8 (1.4)	79 (2.7)		
June 2021	2 (0.3)	10 (0.3)		
July 2021	0 (0.0)	0 (0.0)		
Specimen type			<0.0001	0.4285
NP/OP swab	556 (95.4)	2394 (82.1)		
Saliva (asymptomatic)	27 (4.6)	521 (17.9)		

^a Epsilon variant lineages: B.1.427, B.1.429

^b Defined in the one year prior to specimen collection date

^c Defined in the two years prior to specimen collection date

^d Defined based on all available medical records from March 1, 2020 to specimen collection date

^e Defined as HIV/AIDS; leukemia/lymphoma, congenital and other immunodeficiencies, asplenia/hyposplenias; organ transplant; immunosuppressant medications

^f Defined as rheumatoid arthritis, inflammatory bowel disease, psoriasis and psoriatic arthritis, multiple sclerosis, systemic lupus erythematosus
Medical center area not shown. There were differences in the distribution of cases and controls across the medical center areas.

Abbreviations: ASD, Absolute Standardized Difference; BMI, Body Mass Index; ED, Emergency Department; HIV/AIDS, Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome; NP/OP, nasopharyngeal/oropharyngeal

Table S4. Characteristics of SARS-CoV-2 test-positive Gamma^a cases and test-negative controls (2-dose analysis)

	Test Positive (Gamma) N=349 n (%)	Test Negative N=1745 n (%)	p value	ASD
Age at specimen collection date, years			N/A	N/A
18-44	216 (61.9)	1080 (61.9)		
45-64	97 (27.8)	485 (27.8)		
65-74	24 (6.9)	120 (6.9)		
≥75	12 (3.4)	60 (3.4)		
Sex			N/A	N/A
Female	193 (55.3)	965 (55.3)		
Male	156 (44.7)	780 (44.7)		
Race/ethnicity			N/A	N/A
Non-Hispanic White	96 (27.5)	480 (27.5)		
Non-Hispanic Black	54 (15.5)	270 (15.5)		
Hispanic	163 (46.7)	815 (46.7)		
Non-Hispanic Asian	7 (2.0)	35 (2.0)		
Other/Unknown	29 (8.3)	145 (8.3)		
BMI ^c			0.1450	0.1811
<18.5	7 (2.0)	16 (0.9)		
18.5 - <25	59 (16.9)	349 (20.0)		
25 - <30	95 (27.2)	493 (28.3)		
30 - <35	73 (20.9)	399 (22.9)		
35 - <40	41 (11.7)	205 (11.7)		
40 - <45	18 (5.2)	79 (4.5)		
≥45	11 (3.2)	52 (3.0)		
Unknown	45 (12.9)	152 (8.7)		
Smoking ^c			0.0778	0.1252
No	253 (72.5)	1288 (73.8)		
Yes	61 (17.5)	340 (19.5)		
Unknown	35 (10.0)	117 (6.7)		
Charlson comorbidity score ^b			0.0038	0.2109
0	286 (81.9)	1302 (74.6)		
1	38 (10.9)	213 (12.2)		
≥2	25 (7.2)	230 (13.2)		
Frailty index ^b			0.0039	0.2110
Quartile 1	84 (24.1)	421 (24.1)		
Quartile 2	116 (33.2)	426 (24.4)		
Quartile 3	77 (22.1)	447 (25.6)		
Quartile 4 (most frail)	72 (20.6)	451 (25.8)		
Chronic diseases ^b				
Kidney disease	8 (2.3)	64 (3.7)	0.1980	0.0810
Heart disease	4 (1.1)	44 (2.5)	0.1171	0.1026
Lung disease	17 (4.9)	146 (8.4)	0.0261	0.1410
Liver disease	5 (1.4)	65 (3.7)	0.0296	0.1450
Diabetes	33 (9.5)	177 (10.1)	0.6962	0.0231
Immunocompromised ^e	5 (1.4)	75 (4.3)	0.0108	0.1724
Autoimmune conditions ^{b,f}	5 (1.4)	43 (2.5)	0.2398	0.0747
Pregnant at specimen collection date	8 (2.3)	98 (5.6)	0.0097	0.1712
History of COVID-19 diagnosis ^d	2 (0.6)	116 (6.6)	<0.0001	0.3300
History of SARS-CoV-2 molecular test ^d	174 (49.9)	899 (51.5)	0.5707	0.0332
Number of outpatient and virtual visits ^b			<0.0001	0.3922
0	36 (10.3)	105 (6.0)		
1-4	132 (37.8)	439 (25.2)		
5-10	90 (25.8)	469 (26.9)		
≥11	91 (26.1)	732 (41.9)		

Number of ED visits ^b			0.0004	0.2555
0	304 (87.1)	1367 (78.3)		
1	33 (9.5)	230 (13.2)		
≥2	12 (3.4)	148 (8.5)		
Number of hospitalizations ^b			0.0335	0.1784
0	338 (96.8)	1632 (93.5)		
1	10 (2.9)	82 (4.7)		
≥2	1 (0.3)	31 (1.8)		
Preventive care ^b	179 (51.3)	1155 (66.2)	<0.0001	0.3062
Medicaid	41 (11.7)	189 (10.8)	0.6170	0.0290
Neighborhood median household income			0.4784	0.0988
< \$40,000	17 (4.9)	101 (5.8)		
\$40,000-\$59,999	69 (19.8)	390 (22.3)		
\$60,000-\$79,999	94 (26.9)	434 (24.9)		
\$80,000+	168 (48.1)	819 (46.9)		
Unknown	1 (0.3)	1 (0.1)		
KPSC physician/employee	5 (1.4)	77 (4.4)	0.0088	0.1776
Month of specimen collection			0.1218	0.1562
March 2021	34 (9.7)	196 (11.2)		
April 2021	106 (30.4)	459 (26.3)		
May 2021	92 (26.4)	529 (30.3)		
June 2021	68 (19.5)	374 (21.4)		
July 2021	49 (14.0)	187 (10.7)		
Specimen type			<0.0001	0.4793
NP/OP swab	340 (97.4)	1463 (83.8)		
Saliva (asymptomatic)	9 (2.6)	282 (16.2)		

^a Gamma variant lineages: P.1, P.1.1

^b Defined in the one year prior to specimen collection date

^c Defined in the two years prior to specimen collection date

^d Defined based on all available medical records from March 1, 2020 to specimen collection date

^e Defined as HIV/AIDS; leukemia/lymphoma, congenital and other immunodeficiencies, asplenia/hyposplenia; organ transplant; immunosuppressant medications

^f Defined as rheumatoid arthritis, inflammatory bowel disease, psoriasis and psoriatic arthritis, multiple sclerosis, systemic lupus erythematosus Medical center area not shown. There were differences in the distribution of cases and controls across the medical center areas.

Abbreviations: ASD, Absolute Standardized Difference; BMI, Body Mass Index; ED, Emergency Department; HIV/AIDS, Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome; NP/OP, nasopharyngeal/oropharyngeal

Table S5. Characteristics of SARS-CoV-2 test-positive Iota^a cases and test-negative controls (2-dose analysis)

	Test Positive (Iota) N=114 n (%)	Test Negative N=570 n (%)	p value	ASD
Age at specimen collection date, years			N/A	N/A
18-44	68 (59.6)	340 (59.6)		
45-64	38 (33.3)	190 (33.3)		
65-74	8 (7.0)	40 (7.0)		
≥75	0 (0.0)	0 (0.0)		
Sex			N/A	N/A
Female	72 (63.2)	360 (63.2)		
Male	42 (36.8)	210 (36.8)		
Race/ethnicity			N/A	N/A
Non-Hispanic White	40 (35.1)	200 (35.1)		
Non-Hispanic Black	18 (15.8)	90 (15.8)		
Hispanic	37 (32.5)	185 (32.5)		
Non-Hispanic Asian	7 (6.1)	35 (6.1)		
Other/Unknown	12 (10.5)	60 (10.5)		
BMI ^c			0.8225	0.1984
<18.5	1 (0.9)	6 (1.1)		
18.5 - <25	35 (30.7)	141 (24.7)		
25 - <30	25 (21.9)	142 (24.9)		
30 - <35	23 (20.2)	121 (21.2)		
35 - <40	15 (13.2)	61 (10.7)		
40 - <45	4 (3.5)	23 (4.0)		
≥45	4 (3.5)	21 (3.7)		
Unknown	7 (6.1)	55 (9.6)		
Smoking ^c			0.3144	0.1636
No	88 (77.2)	409 (71.8)		
Yes	16 (14.0)	115 (20.2)		
Unknown	10 (8.8)	46 (8.1)		
Charlson comorbidity score ^b			0.1049	0.2352
0	96 (84.2)	431 (75.6)		
1	11 (9.6)	70 (12.3)		
≥2	7 (6.1)	69 (12.1)		
Frailty index ^b			0.7551	0.1127
Quartile 1	25 (21.9)	135 (23.7)		
Quartile 2	32 (28.1)	146 (25.6)		
Quartile 3	32 (28.1)	143 (25.1)		
Quartile 4 (most frail)	25 (21.9)	146 (25.6)		
Chronic diseases ^b				
Kidney disease	3 (2.6)	17 (3.0)	0.8391	0.0212
Heart disease	2 (1.8)	14 (2.5)	0.6509	0.0489
Lung disease	5 (4.4)	57 (10.0)	0.0567	0.2186
Liver disease	1 (0.9)	17 (3.0)	0.1999	0.1535
Diabetes	3 (2.6)	55 (9.6)	0.0141	0.2955
Immunocompromised ^e	3 (2.6)	25 (4.4)	0.3881	0.0955
Autoimmune conditions ^{b,f}	3 (2.6)	16 (2.8)	0.9171	0.0108
Pregnant at specimen collection date	2 (1.8)	31 (5.4)	0.0938	0.1988
History of COVID-19 diagnosis ^d	1 (0.9)	44 (7.7)	0.0071	0.3423
History of SARS-CoV-2 molecular test ^d	59 (51.8)	298 (52.3)	0.9182	0.0105
Number of outpatient and virtual visits ^b			0.0998	0.2551
0	10 (8.8)	33 (5.8)		
1-4	40 (35.1)	152 (26.7)		
5-10	28 (24.6)	147 (25.8)		
≥11	36 (31.6)	238 (41.6)		

Number of ED visits ^b			0.3980	0.1463
0	98 (86.0)	460 (80.7)		
1	12 (10.5)	78 (13.7)		
≥2	4 (3.5)	32 (5.6)		
Number of hospitalizations ^b			0.1555	0.2373
0	112 (98.2)	535 (93.9)		
1	2 (1.8)	29 (5.1)		
≥2	0 (0.0)	6 (1.1)		
Preventive care ^b	56 (49.1)	379 (66.5)	0.0004	0.3572
Medicaid	10 (8.8)	61 (10.7)	0.5374	0.0651
Neighborhood median household income			0.0475	0.2861
< \$40,000	9 (7.9)	23 (4.0)		
\$40,000-\$59,999	19 (16.7)	120 (21.1)		
\$60,000-\$79,999	19 (16.7)	141 (24.7)		
\$80,000+	67 (58.8)	286 (50.2)		
Unknown	0 (0.0)	0 (0.0)		
KPSC physician/employee	9 (7.9)	24 (4.2)	0.0938	0.1550
Month of specimen collection			0.4537	0.1921
March 2021	29 (25.4)	163 (28.6)		
April 2021	47 (41.2)	191 (33.5)		
May 2021	24 (21.1)	149 (26.1)		
June 2021	12 (10.5)	62 (10.9)		
July 2021	2 (1.8)	5 (0.9)		
Specimen type			<0.0001	0.5208
NP/OP swab	112 (98.2)	478 (83.9)		
Saliva (asymptomatic)	2 (1.8)	92 (16.1)		

^a Iota variant lineages: B.1.526, B.1.526.1, B.1.526.2

^b Defined in the one year prior to specimen collection date

^c Defined in the two years prior to specimen collection date

^d Defined based on all available medical records from March 1, 2020 to specimen collection date

^e Defined as HIV/AIDS; leukemia/lymphoma, congenital and other immunodeficiencies, asplenia/hyposplenia; organ transplant; immunosuppressant medications

^f Defined as rheumatoid arthritis, inflammatory bowel disease, psoriasis and psoriatic arthritis, multiple sclerosis, systemic lupus erythematosus
Medical center area not shown. There were no differences in the distribution of cases and controls across the medical center areas.

Abbreviations: ASD, Absolute Standardized Difference; BMI, Body Mass Index; ED, Emergency Department; HIV/AIDS, Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome; NP/OP, nasopharyngeal/oropharyngeal

Table S6. Characteristics of SARS-CoV-2 test-positive Mu^a cases and test-negative controls (2-dose analysis)

	Test Positive (Mu) N=69 n (%)	Test Negative N=345 n (%)	p value	ASD
Age at specimen collection date, years			N/A	N/A
18-44	46 (66.7)	230 (66.7)		
45-64	21 (30.4)	105 (30.4)		
65-74	2 (2.9)	10 (2.9)		
≥75	0 (0.0)	0 (0.0)		
Sex			N/A	N/A
Female	37 (53.6)	185 (53.6)		
Male	32 (46.4)	160 (46.4)		
Race/ethnicity			N/A	N/A
Non-Hispanic White	23 (33.3)	115 (33.3)		
Non-Hispanic Black	7 (10.1)	35 (10.1)		
Hispanic	28 (40.6)	140 (40.6)		
Non-Hispanic Asian	5 (7.2)	25 (7.2)		
Other/Unknown	6 (8.7)	30 (8.7)		
BMI ^c			0.0949	0.4715
<18.5	0 (0.0)	2 (0.6)		
18.5 - <25	21 (30.4)	77 (22.3)		
25 - <30	12 (17.4)	99 (28.7)		
30 - <35	20 (29.0)	55 (15.9)		
35 - <40	6 (8.7)	40 (11.6)		
40 - <45	3 (4.3)	18 (5.2)		
≥45	1 (1.4)	14 (4.1)		
Unknown	6 (8.7)	40 (11.6)		
Smoking ^c			0.5787	0.1442
No	54 (78.3)	253 (73.3)		
Yes	9 (13.0)	63 (18.3)		
Unknown	6 (8.7)	29 (8.4)		
Charlson comorbidity score ^b			0.2476	0.2425
0	57 (82.6)	262 (75.9)		
1	5 (7.2)	51 (14.8)		
≥2	7 (10.1)	32 (9.3)		
Frailty index ^b			0.9769	0.0600
Quartile 1	18 (26.1)	86 (24.9)		
Quartile 2	17 (24.6)	86 (24.9)		
Quartile 3	18 (26.1)	85 (24.6)		
Quartile 4 (most frail)	16 (23.2)	88 (25.5)		
Chronic diseases ^b				
Kidney disease	0 (0.0)	9 (2.6)	0.1750	0.2315
Heart disease	2 (2.9)	6 (1.7)	0.5230	0.0771
Lung disease	6 (8.7)	25 (7.2)	0.6763	0.0535
Liver disease	1 (1.4)	14 (4.1)	0.2898	0.1599
Diabetes	4 (5.8)	37 (10.7)	0.2110	0.1797
Immunocompromised status	1 (1.4)	11 (3.2)	0.4318	0.1157
Autoimmune conditions ^{b,f}	3 (4.3)	5 (1.4)	0.1103	0.1734
Pregnant at specimen collect date	2 (2.9)	16 (4.6)	0.5178	0.0914
History of COVID-19 diagnosis ^d	1 (1.4)	29 (8.4)	0.0419	0.3256
History of SARS-CoV-2 molecular test ^d	46 (66.7)	161 (46.7)	0.0024	0.4121
Number of outpatient and virtual visits ^b			0.6207	0.1755
0	6 (8.7)	32 (9.3)		
1-4	22 (31.9)	87 (25.2)		
5-10	17 (24.6)	107 (31.0)		
≥11	24 (34.8)	119 (34.5)		

Number of ED visits ^b			0.5225	0.1516
0	56 (81.2)	287 (83.2)		
1	11 (15.9)	41 (11.9)		
≥2	2 (2.9)	17 (4.9)		
Number of hospitalizations ^b			0.5620	0.1791
0	67 (97.1)	327 (94.8)		
1	2 (2.9)	13 (3.8)		
≥2	0 (0.0)	5 (1.4)		
Preventive care ^b	41 (59.4)	211 (61.2)	0.7870	0.0355
Medicaid	5 (7.2)	36 (10.4)	0.4183	0.1125
Neighborhood median household income			0.8166	0.1755
< \$40,000	4 (5.8)	20 (5.8)		
\$40,000-\$59,999	12 (17.4)	55 (15.9)		
\$60,000-\$79,999	15 (21.7)	98 (28.4)		
\$80,000+	38 (55.1)	171 (49.6)		
Unknown	0 (0.0)	1 (0.3)		
KPSC physician/employee	5 (7.2)	13 (3.8)	0.1959	0.1529
Month of specimen collection			0.0168	0.3668
March 2021	0 (0.0)	0 (0.0)		
April 2021	1 (1.4)	0 (0.0)		
May 2021	5 (7.2)	27 (7.8)		
June 2021	12 (17.4)	107 (31.0)		
July 2021	51 (73.9)	211 (61.2)		
Specimen type			0.0213	0.3527
NP/OP swab	66 (95.7)	295 (85.5)		
Saliva (asymptomatic)	3 (4.3)	50 (14.5)		

^a Mu variant lineages: B.1.621, B.1.621.1

^b Defined in the one year prior to specimen collection date

^c Defined in the two years prior to specimen collection date

^d Defined based on all available medical records from March 1, 2020 to specimen collection date

^e Defined as HIV/AIDS; leukemia/lymphoma, congenital and other immunodeficiencies, asplenia/hyposplenia; organ transplant; immunosuppressant medications

^f Defined as rheumatoid arthritis, inflammatory bowel disease, psoriasis and psoriatic arthritis, multiple sclerosis, systemic lupus erythematosus
Medical center area not shown. There were no differences in the distribution of cases and controls across the medical center areas.

Abbreviations: ASD, Absolute Standardized Difference; BMI, Body Mass Index; ED, Emergency Department; HIV/AIDS, Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome; NP/OP, nasopharyngeal/oropharyngeal

Table S7. Characteristics of SARS-CoV-2 test-positive other^a variant cases and test-negative controls (2-dose analysis)

	Test Positive (Beta, Eta, Kappa, and other variants) N=568 n (%)	Test Negative N=2840 n (%)	p value	ASD
Age at specimen collection date, years			N/A	N/A
18-44	324 (57.0)	1620 (57.0)		
45-64	200 (35.2)	1000 (35.2)		
65-74	32 (5.6)	160 (5.6)		
≥75	12 (2.1)	60 (2.1)		
Sex			N/A	N/A
Female	307 (54.0)	1535 (54.0)		
Male	261 (46.0)	1305 (46.0)		
Race/ethnicity			N/A	N/A
Non-Hispanic White	162 (28.5)	810 (28.5)		
Non-Hispanic Black	53 (9.3)	265 (9.3)		
Hispanic	303 (53.3)	1515 (53.3)		
Non-Hispanic Asian	20 (3.5)	100 (3.5)		
Other/Unknown	30 (5.3)	150 (5.3)		
BMI ^b			0.0806	0.1584
<18.5	5 (0.9)	39 (1.4)		
18.5 - <25	110 (19.4)	595 (21.0)		
25 - <30	171 (30.1)	861 (30.3)		
30 - <35	122 (21.5)	610 (21.5)		
35 - <40	57 (10.0)	284 (10.0)		
40 - <45	18 (3.2)	128 (4.5)		
≥45	19 (3.3)	106 (3.7)		
Unknown	66 (11.6)	217 (7.6)		
Smoking ^b			0.0095	0.1352
No	426 (75.0)	2121 (74.7)		
Yes	91 (16.0)	549 (19.3)		
Unknown	51 (9.0)	170 (6.0)		
Charlson comorbidity score ^a			0.0052	0.1593
0	449 (79.0)	2122 (74.7)		
1	75 (13.2)	362 (12.7)		
≥2	44 (7.7)	356 (12.5)		
Frailty index ^a			0.0007	0.1892
Quartile 1	141 (24.8)	711 (25.0)		
Quartile 2	176 (31.0)	676 (23.8)		
Quartile 3	138 (24.3)	714 (25.1)		
Quartile 4 (most frail)	113 (19.9)	739 (26.0)		
Chronic diseases ^a				
Kidney disease	11 (1.9)	111 (3.9)	0.0209	0.1173
Heart disease	7 (1.2)	88 (3.1)	0.0136	0.1285
Lung disease	37 (6.5)	234 (8.2)	0.1653	0.0660
Liver disease	16 (2.8)	116 (4.1)	0.1529	0.0695
Diabetes	49 (8.6)	318 (11.2)	0.0712	0.0861
Immunocompromised ^d	16 (2.8)	125 (4.4)	0.0835	0.0850
Autoimmune conditions ^{a,e}	14 (2.5)	103 (3.6)	0.1650	0.0677
Pregnant at specimen collection date	11 (1.9)	152 (5.4)	0.0005	0.1830
History of COVID-19 diagnosis ^c	4 (0.7)	225 (7.9)	<0.0001	0.3610
History of SARS-CoV-2 molecular test ^c	311 (54.8)	1541 (54.3)	0.8295	0.0099
Number of outpatient and virtual visits ^a			<0.0001	0.3373
0	56 (9.9)	193 (6.8)		
1-4	197 (34.7)	730 (25.7)		

5-10	169 (29.8)	756 (26.6)		
≥11	146 (25.7)	1161 (40.9)		
Number of ED visits ^a			<0.0001	0.2350
0	489 (86.1)	2215 (78.0)		
1	60 (10.6)	403 (14.2)		
≥2	19 (3.3)	222 (7.8)		
Number of hospitalizations ^a			0.0003	0.2174
0	548 (96.5)	2615 (92.1)		
1	19 (3.3)	169 (6.0)		
≥2	1 (0.2)	56 (2.0)		
Preventive care ^a	309 (54.4)	1867 (65.7)	<0.0001	0.2331
Medicaid	44 (7.7)	303 (10.7)	0.0355	0.1012
Neighborhood median household income			0.7262	0.0699
< \$40,000	27 (4.8)	147 (5.2)		
\$40,000-\$59,999	123 (21.7)	645 (22.7)		
\$60,000-\$79,999	137 (24.1)	725 (25.5)		
\$80,000+	281 (49.5)	1321 (46.5)		
Unknown	0 (0.0)	2 (0.1)		
KPSC physician/employee	18 (3.2)	104 (3.7)	0.5638	0.0271
Month of specimen collection			0.0003	0.1943
March 2021	284 (50.0)	1496 (52.7)		
April 2021	193 (34.0)	835 (29.4)		
May 2021	53 (9.3)	323 (11.4)		
June 2021	20 (3.5)	152 (5.4)		
July 2021	18 (3.2)	34 (1.2)		
Specimen type			<0.0001	0.4570
NP/OP swab	550 (96.8)	2374 (83.6)		
Saliva (asymptomatic)	18 (3.2)	466 (16.4)		

^a Other variant lineages: A, A.2, A.2.5, A.2.5.1, A.5, B, B.1, B.1.1, B.1.1.174, B.1.1.222, B.1.1.28, B.1.1.304, B.1.1.316, B.1.1.318, B.1.1.328, B.1.1.335, B.1.1.368, B.1.1.378, B.1.1.413, B.1.1.416, B.1.1.432, B.1.1.519, B.1.126, B.1.153, B.1.160, B.1.2, B.1.232, B.1.234, B.1.241, B.1.243, B.1.280, B.1.289, B.1.311, B.1.324, B.1.349, B.1.351 (Beta), B.1.351.3 (Beta), B.1.36.21, B.1.377, B.1.384, B.1.393, B.1.396, B.1.400, B.1.404, B.1.438.1, B.1.441, B.1.523, B.1.525 (Eta), B.1.530, B.1.550, B.1.551, B.1.555, B.1.561, B.1.575, B.1.577, B.1.595, B.1.596, B.1.599, B.1.604, B.1.609, B.1.612, B.1.617.1 (Kappa), B.1.619, B.1.623, B.1.628, C.36, C.37 (Lambda), D.2, P.2 (Zeta), R.1

^b Defined in the one year prior to specimen collection date

^c Defined in the two years prior to specimen collection date

^d Defined based on all available medical records from March 1, 2020 to specimen collection date

^e Defined as HIV/AIDS; leukemia/lymphoma, congenital and other immunodeficiencies, asplenia/hyposplenia; organ transplant; immunosuppressant medications

^f Defined as rheumatoid arthritis, inflammatory bowel disease, psoriasis and psoriatic arthritis, multiple sclerosis, systemic lupus erythematosus
Medical center area not shown. There were differences in the distribution of cases and controls across the medical center areas.

Abbreviations: ASD, Absolute Standardized Difference; BMI, Body Mass Index; ED, Emergency Department; HIV/AIDS, Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome; NP/OP, nasopharyngeal/oropharyngeal

Table S8. Characteristics of SARS-CoV-2 test-positive unidentified variants cases and test-negative controls (2-dose analysis)

	Test Positive (Unidentified variants) N=2909 n (%)	Test Negative N=14545 n (%)	p value	ASD
Age at specimen collection date, years			N/A	N/A
18-44	1784 (61.3)	8920 (61.3)		
45-64	869 (29.9)	4345 (29.9)		
65-74	179 (6.2)	895 (6.2)		
≥75	77 (2.6)	385 (2.6)		
Sex			N/A	N/A
Female	1618 (55.6)	8090 (55.6)		
Male	1291 (44.4)	6455 (44.4)		
Race/ethnicity			N/A	N/A
Non-Hispanic White	786 (27.0)	3930 (27.0)		
Non-Hispanic Black	427 (14.7)	2135 (14.7)		
Hispanic	1333 (45.8)	6665 (45.8)		
Non-Hispanic Asian	155 (5.3)	775 (5.3)		
Other/Unknown	208 (7.2)	1040 (7.2)		
BMI ^b			<0.0001	0.1378
<18.5	29 (1.0)	172 (1.2)		
18.5 - <25	600 (20.6)	3120 (21.5)		
25 - <30	803 (27.6)	4099 (28.2)		
30 - <35	575 (19.8)	3118 (21.4)		
35 - <40	306 (10.5)	1563 (10.7)		
40 - <45	132 (4.5)	721 (5.0)		
≥45	85 (2.9)	467 (3.2)		
Unknown	379 (13.0)	1285 (8.8)		
Smoking ^b			<0.0001	0.1533
No	2143 (73.7)	10811 (74.3)		
Yes	454 (15.6)	2740 (18.8)		
Unknown	312 (10.7)	994 (6.8)		
Charlson comorbidity score ^a			<0.0001	0.1134
0	2321 (79.8)	10962 (75.4)		
1	324 (11.1)	1822 (12.5)		
≥2	264 (9.1)	1761 (12.1)		
Frailty index ^a			<0.0001	0.1763
Quartile 1	690 (23.7)	3626 (24.9)		
Quartile 2	912 (31.4)	3499 (24.1)		
Quartile 3	700 (24.1)	3664 (25.2)		
Quartile 4 (most frail)	607 (20.9)	3756 (25.8)		
Chronic diseases ^a				
Kidney disease	86 (3.0)	487 (3.3)	0.2789	0.0224
Heart disease	57 (2.0)	362 (2.5)	0.0886	0.0359
Lung disease	221 (7.6)	1215 (8.4)	0.1754	0.0279
Liver disease	55 (1.9)	498 (3.4)	<0.0001	0.0954
Diabetes	247 (8.5)	1532 (10.5)	0.0009	0.0696
Immunocompromised ^d	87 (3.0)	644 (4.4)	0.0004	0.0761
Autoimmune conditions ^{a,e}	51 (1.8)	406 (2.8)	0.0014	0.0697
Pregnant at specimen collection date	74 (2.5)	742 (5.1)	<0.0001	0.1337
History of COVID-19 diagnosis ^c	94 (3.2)	1100 (7.6)	<0.0001	0.1926
History of SARS-CoV-2 molecular test ^c	1474 (50.7)	7554 (51.9)	0.2126	0.0253
Number of outpatient and virtual visits ^a			<0.0001	0.2619
0	323 (11.1)	963 (6.6)		
1-4	960 (33.0)	3908 (26.9)		
5-10	781 (26.8)	3920 (27.0)		

≥ 11	845 (29.0)	5754 (39.6)		
Number of ED visits ^a			<0.0001	0.1321
0	2439 (83.8)	11475 (78.9)		
1	325 (11.2)	2004 (13.8)		
≥ 2	145 (5.0)	1066 (7.3)		
Number of hospitalizations ^a			0.0003	0.0919
0	2764 (95.0)	13660 (93.9)		
1	126 (4.3)	649 (4.5)		
≥ 2	19 (0.7)	236 (1.6)		
Preventive care ^a	1517 (52.1)	9568 (65.8)	<0.0001	0.2799
Medicaid	306 (10.5)	1485 (10.2)	0.6157	0.0102
Neighborhood median household income			0.0342	0.0654
< \$40,000	163 (5.6)	806 (5.5)		
\$40,000-\$59,999	657 (22.6)	3175 (21.8)		
\$60,000-\$79,999	797 (27.4)	3657 (25.1)		
\$80,000+	1289 (44.3)	6893 (47.4)		
Unknown	3 (0.1)	14 (0.1)		
KPSC physician/employee	100 (3.4)	649 (4.5)	0.0128	0.0526
Month of specimen collection			<0.0001	0.1860
March 2021	608 (20.9)	3142 (21.6)		
April 2021	499 (17.2)	2156 (14.8)		
May 2021	359 (12.3)	2124 (14.6)		
June 2021	469 (16.1)	3122 (21.5)		
July 2021	974 (33.5)	4001 (27.5)		
Specimen type			<0.0001	0.2096
NP/OP swab	2644 (90.9)	12215 (84.0)		
Saliva (asymptomatic)	265 (9.1)	2330 (16.0)		

^a Defined in the one year prior to specimen collection date

^b Defined in the two years prior to specimen collection date

^c Defined based on all available medical records from March 1, 2020 to specimen collection date

^d Defined as HIV/AIDS; leukemia/lymphoma, congenital and other immunodeficiencies, asplenia/hyposplenia; organ transplant; immunosuppressant medications

^e Defined as rheumatoid arthritis, inflammatory bowel disease, psoriasis and psoriatic arthritis, multiple sclerosis, systemic lupus erythematosus
Medical center area not shown. There were differences in the distribution of cases and controls across the medical center areas.

Abbreviations: ASD, Absolute Standardized Difference; BMI, Body Mass Index; ED, Emergency Department; HIV/AIDS, Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome; NP/OP, nasopharyngeal/oropharyngeal

Table S9. Vaccine effectiveness of 2 doses of mRNA-1273 against infection with SARS-CoV-2 variants

	Test Positive		Test Negative		Odds Ratio (95% CI)		VE (95% CI)	
	Vaccinated n (%)	Unvaccinated n (%)	Vaccinated n (%)	Unvaccinated n (%)	Unadjusted	Adjusted ^a	Unadjusted (%)	Adjusted ^a (%)
Alpha	13 (0.9)	1409 (99.1)	1734 (24.4)	5376 (75.6%)	0.019 (0.010, 0.034)	0.016 (0.009, 0.031)	98.1 (96.6, 99.0)	98.4 (96.9, 99.1)
Delta	232 (11.4)	1795 (88.6)	4588 (45.3)	5547 (54.7%)	0.134 (0.115, 0.156)	0.133 (0.113, 0.157)	86.6 (84.4, 88.5)	86.7 (84.3, 88.7)
Epsilon	3 (0.5)	580 (99.5)	317 (10.9)	2598 (89.1%)	0.024 (0.006, 0.097)	0.024 (0.006, 0.098)	97.6 (90.3, 99.4)	97.6 (90.2, 99.4)
Gamma	9 (2.6)	340 (97.4)	552 (31.6)	1193 (68.4%)	0.044 (0.022, 0.087)	0.045 (0.022, 0.091)	95.6 (91.3, 97.8)	95.5 (90.9, 97.8)
Iota	3 (2.6)	111 (97.4)	122 (21.4)	448 (78.6%)	0.076 (0.023, 0.252)	0.043 (0.010, 0.183)	92.4 (74.8, 97.7)	95.7 (81.7, 99.0)
Mu	7 (10.1)	62 (89.9)	153 (44.3)	192 (55.7%)	0.111 (0.046, 0.267)	0.096 (0.035, 0.261)	88.9 (73.3, 95.4)	90.4 (73.9, 96.5)
Other	6 (1.1)	562 (98.9)	457 (16.1)	2383 (83.9%)	0.041 (0.018, 0.094)	0.036 (0.015, 0.088)	95.9 (90.6, 98.2)	96.4 (91.2, 98.5)
Unidentified	326 (11.2)	2583 (88.8)	4856 (33.4)	9689 (66.6%)	0.193 (0.170, 0.220)	0.201 (0.175, 0.231)	80.7 (78.0, 83.0)	79.9 (76.9, 82.5)

^a Model adjustment:

Model for Alpha variant adjusted for covariates: BMI, smoking, Charlson comorbidity score, frailty index, lung disease, immunocompromised status, pregnancy, history of COVID-19 diagnosis, number of outpatient and virtual visits, number of ED visits, number of hospitalizations, preventive care, medical center area, month of specimen collection, specimen type.

Model for Delta variant adjusted for covariates: smoking, Charlson comorbidity score, frailty index, liver disease, pregnancy, history of COVID-19 diagnosis, number of outpatient and virtual visits, preventive care, medical center area, month of specimen collection, specimen type.

Model for Epsilon variant adjusted for covariates: BMI, smoking, Charlson comorbidity score, frailty index, kidney disease, heart disease, lung disease, diabetes, immunocompromised status, pregnancy, history of COVID-19 diagnosis, history of SARS-CoV-2 molecular test, number of outpatient and virtual visits, number of ED visits, number of hospitalizations, preventive care, medical center area, specimen type.

Model for Gamma variant adjusted for covariates: smoking, Charlson comorbidity score, frailty index, lung disease, liver disease, immunocompromised status, pregnancy, history of COVID-19 diagnosis, number of outpatient and virtual visits, number of ED visits, number of hospitalizations, preventive care, KPSC physician/employee status, medical center area, specimen type.

Model for Iota variant adjusted for covariates: lung disease, diabetes, pregnancy, history of COVID-19 diagnosis, number of outpatient and virtual visits, preventive care, neighborhood median household income, KPSC physician/employee status, specimen type.

Model for Mu variant adjusted for covariates: BMI, history of COVID-19 diagnosis, history of SARS-CoV-2 molecular test, month of specimen collection, specimen type.

Model for Other variants adjusted for covariates: BMI, smoking, Charlson comorbidity score, frailty index, kidney disease, heart disease, pregnancy, history of COVID-19 diagnosis, number of outpatient and virtual visits, number of ED visits, number of hospitalizations, preventive care, Medicaid, medical center area, month of specimen collection, specimen type.

Model for Unidentified variants adjusted for covariates: BMI, smoking, Charlson comorbidity score, frailty index, pregnancy, history of COVID-19 diagnosis, number of outpatient and virtual visits, number of ED visits, preventive care, medical center area, month of specimen collection, specimen type.

Abbreviations: BMI, Body Mass Index; CI, Confidence Interval; ED, Emergency Department

Table S10. Vaccine effectiveness of 1 dose of mRNA-1273 against infection with SARS-CoV-2 variants

	Test Positive		Test Negative		Odds Ratio (95% CI)		VE (95% CI)	
	Vaccinated n (%)	Unvaccinated n (%)	Vaccinated n (%)	Unvaccinated n (%)	Unadjusted	Adjusted ^a	Unadjusted	Adjusted ^a
Alpha	14 (1.0)	1409 (99.0)	635 (8.9)	6480 (91.1)	0.098 (0.057, 0.167)	0.099 (0.058, 0.171)	90.2 (83.3, 94.3)	90.1 (82.9, 94.2)
Delta	15 (0.8)	1795 (99.2)	336 (3.7)	8714 (96.3)	0.215 (0.128, 0.362)	0.230 (0.135, 0.393)	78.5 (63.8, 87.2)	77.0 (60.7, 86.5)
Epsilon	7 (1.2)	580 (98.8)	149 (5.1)	2786 (94.9)	0.212 (0.098, 0.459)	0.237 (0.109, 0.519)	78.8 (54.1, 90.2)	76.3 (48.1, 89.1)
Gamma	8 (2.3)	340 (97.7)	132 (7.6)	1608 (92.4)	0.275 (0.132, 0.572)	0.258 (0.119, 0.562)	72.5 (42.8, 86.8)	74.2 (43.8, 88.1)
Iota	1 (0.9)	111 (99.1)	29 (5.2)	531 (94.8)	0.164 (0.022, 1.216)	0.112 (0.013, 0.993)	83.6 (0.0, 97.8)	88.8 (0.7, 98.7)
Mu	2 (3.1)	62 (96.9)	16 (5.0)	304 (95.0)	0.614 (0.138, 2.732)	0.542 (0.111, 2.644)	38.6 (0.0, 86.2)	45.8 (0.0, 88.9)
Other	7 (1.2)	562 (98.8)	205 (7.2)	2640 (92.8)	0.155 (0.072, 0.333)	0.157 (0.073, 0.341)	84.5 (66.7, 92.8)	84.3 (65.9, 92.7)
Unidentified	58 (2.2)	2583 (97.8)	828 (6.3)	12377 (93.7)	0.326 (0.248, 0.428)	0.324 (0.244, 0.429)	67.4 (57.2, 75.2)	67.6 (57.1, 75.6)

^a Model adjustment:

Model for Alpha variant adjusted for covariates: BMI, smoking, Charlson comorbidity score, frailty index, liver disease, immunocompromised status, pregnancy, history of COVID-19 diagnosis, number of outpatient and virtual visits, number of ED visits, number of hospitalizations, preventive care, medical center area, specimen type.

Model for Delta variant adjusted for covariates: Charlson comorbidity score, frailty index, liver disease, pregnancy, history of COVID-19 diagnosis, number of outpatient and virtual visits, number of ED visits, preventive care, medical center area, month of specimen collection, specimen type.

Model for Epsilon variant adjusted for covariates: BMI, smoking, Charlson comorbidity score, frailty index, heart disease, lung disease, liver disease, pregnancy, history of COVID-19 diagnosis, number of outpatient and virtual visits, number of ED visits, number of hospitalizations, preventive care, medical center area, specimen type.

Model for Gamma variant adjusted for covariates: Charlson comorbidity score, frailty index, heart disease, lung disease, liver disease, immunocompromised status, pregnancy, history of COVID-19 diagnosis, number of outpatient and virtual visits, number of ED visits, number of hospitalizations, preventive care, KPSC physician/employee status, medical center area, specimen type.

Model for Iota variant adjusted for covariates: Charlson comorbidity score, lung disease, diabetes, pregnancy, history of COVID-19 diagnosis, number of outpatient and virtual visits, preventive care, KPSC physician/employee status, medical center area, specimen type.

Model for Mu variant adjusted for covariates: BMI, history of COVID-19 diagnosis, history of SARS-CoV-2 molecular test, month of specimen collection, specimen type.

Model for Other variants adjusted for covariates: smoking, Charlson comorbidity score, frailty index, kidney disease, pregnancy, history of COVID-19 diagnosis, number of outpatient and virtual visits, number of ED visits, number of hospitalizations, preventive care, Medicaid, medical center area, month of specimen collection, specimen type.

Model for Unidentified variants adjusted for covariates: BMI, smoking, Charlson comorbidity score, frailty index, liver disease, pregnancy, history of COVID-19 diagnosis, number of outpatient and virtual visits, number of ED visits, preventive care, medical center area, month of specimen collection, specimen type.

Abbreviations: BMI, Body Mass Index; CI, Confidence Interval; ED, Emergency Department

Table S11. Vaccine effectiveness of 2 doses of mRNA-1273 against infection with SARS-CoV-2 variants by time since vaccination

	Test Positive		Test Negative		Odds Ratio (95% CI)		VE (95% CI)	
	Vaccinated n (%)	Unvaccinated n (%)	Vaccinated n (%)	Unvaccinated n (%)	Unadjusted	Adjusted ^a	Unadjusted (%)	Adjusted ^a (%)
Delta								
14-60 days	21 (1.0)	1795 (88.6)	977 (9.6)	5547 (54.7)	0.060 (0.039, 0.093)	0.059 (0.037, 0.095)	94.0 (90.7, 96.1)	94.1 (90.5, 96.3)
61-90 days	58 (2.9)	1795 (88.6)	1465 (14.5)	5547 (54.7)	0.110 (0.084, 0.145)	0.113 (0.085, 0.150)	89.0 (85.5, 91.6)	88.7 (85.0, 91.5)
91-120 days	56 (2.8)	1795 (88.6)	1023 (10.1)	5547 (54.7)	0.141 (0.106, 0.187)	0.141 (0.105, 0.189)	85.9 (81.3, 89.4)	85.9 (81.1, 89.5)
121-150 days	66 (3.3)	1795 (88.6)	710 (7.0)	5547 (54.7)	0.232 (0.177, 0.304)	0.230 (0.171, 0.309)	76.8 (69.6, 82.3)	77.0 (69.1, 82.9)
151-180 days	31 (1.5)	1795 (88.6)	395 (3.9)	5547 (54.7)	0.217 (0.149, 0.316)	0.200 (0.134, 0.298)	78.3 (68.4, 85.1)	80.0 (70.2, 86.6)
>180 days	0 (0.0)	1795 (88.6)	18 (0.2)	5547 (54.7)	N/E	N/E	N/E	N/E
Non-Delta								
14-60 days	11 (0.4)	3064 (98.7)	2107 (13.6)	12190 (78.5)	0.014 (0.008, 0.027)	0.014 (0.007, 0.027)	98.6 (97.3, 99.2)	98.6 (97.3, 99.3)
61-90 days	10 (0.3)	3064 (98.7)	737 (4.7)	12190 (78.5)	0.031 (0.016, 0.061)	0.031 (0.015, 0.061)	96.9 (93.9, 98.4)	96.9 (93.9, 98.5)
91-120 days	12 (0.4)	3064 (98.7)	321 (2.1)	12190 (78.5)	0.104 (0.058, 0.187)	0.086 (0.046, 0.161)	89.6 (81.3, 94.2)	91.4 (83.9, 95.4)
121-150 days	8 (0.3)	3064 (98.7)	127 (0.8)	12190 (78.5)	0.153 (0.072, 0.325)	0.113 (0.048, 0.268)	84.7 (67.5, 92.8)	88.7 (73.2, 95.2)
151-180 days	0 (0.0)	3064 (98.7)	41 (0.3)	12190 (78.5)	N/E	N/E	N/E	N/E
>180 days	0 (0.0)	3064 (98.7)	2 (0.0)	12190 (78.5)	N/E	N/E	N/E	N/E
Unidentified								
14-60 days	97 (3.3)	2583 (88.8)	2027 (13.9)	9689 (66.6)	0.150 (0.121, 0.186)	0.164 (0.131, 0.205)	85.0 (81.4, 87.9)	83.6 (79.5, 86.9)
61-90 days	76 (2.6)	2583 (88.8)	1267 (8.7)	9689 (66.6)	0.167 (0.131, 0.214)	0.178 (0.138, 0.230)	83.3 (78.6, 86.9)	82.2 (77.0, 86.2)
91-120 days	68 (2.3)	2583 (88.8)	867 (6.0)	9689 (66.6)	0.218 (0.168, 0.284)	0.223 (0.170, 0.293)	78.2 (71.6, 83.2)	77.7 (70.7, 83.0)
121-150 days	59 (2.0)	2583 (88.8)	454 (3.1)	9689 (66.6)	0.355 (0.264, 0.477)	0.336 (0.244, 0.464)	64.5 (52.3, 73.6)	66.4 (53.6, 75.6)
151-180 days	26 (0.9)	2583 (88.8)	232 (1.6)	9689 (66.6)	0.317 (0.208, 0.483)	0.315 (0.204, 0.487)	68.3 (51.7, 79.2)	68.5 (51.3, 79.6)
>180 days	0 (0.0)	2583 (88.8)	9 (0.1)	9689 (66.6)	N/E	N/E	N/E	N/E

a Model adjustment:


Model for Delta adjusted for covariates: smoking, Charlson comorbidity score, frailty index, liver disease, pregnancy, history of COVID-19 diagnosis, number of outpatient and virtual visits, preventive care, medical center area, month of specimen collection, specimen type.

Model for Non-Delta variant adjusted for covariates: BMI, smoking, Charlson comorbidity score, frailty index, kidney disease, heart disease, lung disease, immunocompromised status, pregnancy, history of COVID-19 diagnosis, number of outpatient and virtual visits, number of ED visits, number of hospitalizations, preventive care, medical center area, month of specimen collection, specimen type.

Model for Unidentified variants adjusted for covariates: BMI, smoking, Charlson comorbidity score, frailty index, pregnancy, history of COVID-19 diagnosis, number of outpatient and virtual visits, number of ED visits, preventive care, medical center area, month of specimen collection, specimen type.

Abbreviations: BMI, Body Mass Index; CI, Confidence Interval; ED, Emergency Department; N/E, Not Estimable

Figure S1. Distribution of SARS-CoV-2 variants by mRNA-1273 vaccination status



Variant lineages:

Alpha: B.1.1.7

Delta: AY.1, AY.2, AY.3, B.1.617.2

Epsilon: B.1.427, B.1.429


Gamma: P.1, P.1.1

Iota: B.1.526, B.1.526.1, B.1.526.2

Mu: B.1.621, B.1.621.1

Other (Beta, Eta, Kappa, and other variants): A, A.2, A.2.5, A.2.5.1, A.5, B, B.1, B.1.1, B.1.1.174, B.1.1.222, B.1.1.28, B.1.1.304, B.1.1.316, B.1.1.318, B.1.1.328, B.1.1.335, B.1.1.368, B.1.1.378, B.1.1.413, B.1.1.416, B.1.1.432, B.1.1.519, B.1.126, B.1.153, B.1.160, B.1.2, B.1.232, B.1.234, B.1.241, B.1.243, B.1.280, B.1.289, B.1.311, B.1.324, B.1.349, B.1.351 (Beta), B.1.351.3 (Beta), B.1.36.21, B.1.377, B.1.384, B.1.393, B.1.396, B.1.400, B.1.404, B.1.438.1, B.1.441, B.1.523, B.1.525 (Eta), B.1.530, B.1.550, B.1.551, B.1.555, B.1.561, B.1.575, B.1.577, B.1.595, B.1.596, B.1.599, B.1.604, B.1.609, B.1.612, B.1.617.1 (Kappa), B.1.619, B.1.623, B.1.628, C.36, C.37 (Lambda), D.2, P.2 (Zeta), R.1

Figure S2. Distribution of SARS-CoV-2 variants by month of specimen collection



Variant lineages:

Alpha: B.1.1.7

Delta: AY.1, AY.2, AY.3, B.1.617.2

Epsilon: B.1.427, B.1.429


Gamma: P.1, P.1.1

Iota: B.1.526, B.1.526.1, B.1.526.2

Mu: B.1.621, B.1.621.1

Other (Beta, Eta, Kappa, and other variants): A, A.2, A.2.5, A.2.5.1, A.5, B, B.1, B.1.1, B.1.1.174, B.1.1.222, B.1.1.28, B.1.1.304, B.1.1.316, B.1.1.318, B.1.1.328, B.1.1.335, B.1.1.368, B.1.1.378, B.1.1.413, B.1.1.416, B.1.1.432, B.1.1.519, B.1.126, B.1.153, B.1.160, B.1.2, B.1.232, B.1.234, B.1.241, B.1.243, B.1.280, B.1.289, B.1.311, B.1.324, B.1.349, B.1.351 (Beta), B.1.351.3 (Beta), B.1.36.21, B.1.377, B.1.384, B.1.393, B.1.396, B.1.400, B.1.404, B.1.438.1, B.1.441, B.1.523, B.1.525 (Eta), B.1.530, B.1.550, B.1.551, B.1.555, B.1.561, B.1.575, B.1.577, B.1.595, B.1.596, B.1.599, B.1.604, B.1.609, B.1.612, B.1.617.1 (Kappa), B.1.619, B.1.623, B.1.628, C.36, C.37 (Lambda), D.2, P.2 (Zeta), R.1

Figure S3. Vaccine effectiveness of 2 doses of mRNA-1273 against Delta infection by time since vaccination and age group



	Test Positive		Test Negative		Adjusted ^a VE (95%CI)
	Vaccinated n (%)	Unvaccinated n (%)	Vaccinated n (%)	Unvaccinated n (%)	
Age 18-64 years					
Overall	185 (9.7)	1721 (90.3)	4137 (43.4)	5393 (56.6)	87.9 (85.5, 89.9)
14-60 days	17 (0.9)	1721 (90.3)	948 (9.9)	5393 (56.6)	95.1 (91.8, 97.1)
61-90 days	53 (2.8)	1721 (90.3)	1397 (14.7)	5393 (56.6)	89.2 (85.4, 92.0)
91-120 days	46 (2.4)	1721 (90.3)	872 (9.2)	5393 (56.6)	86.2 (80.9, 90.1)
121-150 days	39 (2.0)	1721 (90.3)	536 (5.6)	5393 (56.6)	80.4 (71.7, 86.4)
151-180 days	30 (1.6)	1721 (90.3)	366 (3.8)	5393 (56.6)	79.4 (68.8, 86.3)
Age 65 years and older					
Overall	47 (38.8)	74 (61.2)	451 (74.5)	154 (25.5)	75.2 (59.6, 84.8)
14-60 days	4 (3.3)	74 (61.2)	29 (4.8)	154 (25.5)	52.9 (0.0, 86.6)
61-90 days	5 (4.1)	74 (61.2)	68 (11.2)	154 (25.5)	85.7 (57.9, 95.1)
91-120 days	10 (8.3)	74 (61.2)	151 (25.0)	154 (25.5)	85.8 (68.9, 93.5)
121-150 days	27 (22.3)	74 (61.2)	174 (28.8)	154 (25.5)	62.3 (32.4, 79.0)
151-180 days	1 (0.8)	74 (61.2)	29 (4.8)	154 (25.5)	90.8 (25.6, 98.9)

^aModel adjusted for smoking, Charlson comorbidity score, frailty index, liver disease, pregnancy, history of COVID-19 diagnosis, number of outpatient and virtual visits, preventive care, medical center area, month of specimen collection, specimen type.